Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2013 1
2014 3
2015 5
2016 4
2017 3
2018 2
2019 7
2020 12
2021 12
2022 19
2023 24
2024 29
2025 19
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
CONCLUSIONS: Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients achieving extended dosing intervals. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and …
CONCLUSIONS: Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients …
Reply.
Friedrich M, Hofmann CA, Chychko L, Son HS, Khoramnia R, Auffarth GU, Augustin VA. Friedrich M, et al. Cornea. 2024 Sep 1;43(9):e20. doi: 10.1097/ICO.0000000000003576. Epub 2024 May 17. Cornea. 2024. PMID: 38759147 No abstract available.
Refractive Outcomes after Cataract Surgery.
Khoramnia R, Auffarth G, Łabuz G, Pettit G, Suryakumar R. Khoramnia R, et al. Diagnostics (Basel). 2022 Jan 19;12(2):243. doi: 10.3390/diagnostics12020243. Diagnostics (Basel). 2022. PMID: 35204334 Free PMC article. Review.
Characterisation of Intraocular Lens Injectors.
Friedrich M, Munro DJ, Auffarth GU, Khoramnia R. Friedrich M, et al. Klin Monbl Augenheilkd. 2024 Aug;241(8):905-916. doi: 10.1055/a-2349-2158. Epub 2024 Aug 15. Klin Monbl Augenheilkd. 2024. PMID: 39146575 Review. English.
In modern ophthalmic surgery, an intraocular lens (IOL) is commonly implanted into the patient's eye with an IOL injector. Many injectors are available, showing various technological differences, from the early manually loaded injector systems to the modern preloaded injec …
In modern ophthalmic surgery, an intraocular lens (IOL) is commonly implanted into the patient's eye with an IOL injector. Many injec …
Anterior Segment Complications Following Intravitreal Injection.
Mackenbrock LHB, Auffarth GU, Albrecht M, Naujokaitis T, Kessler LJ, Mayer CS, Khoramnia R. Mackenbrock LHB, et al. Klin Monbl Augenheilkd. 2024 Aug;241(8):917-922. doi: 10.1055/a-2349-2224. Epub 2024 Aug 15. Klin Monbl Augenheilkd. 2024. PMID: 39146576 Review. English.
Intravitreal injections (IVI s) have gained increased popularity in the past decades and are used to treat a multitude of ailments. In 2010, the total number of IVI s surpassed the number of cataract surgeries performed, making it the most common procedure in ophtha …
Intravitreal injections (IVI s) have gained increased popularity in the past decades and are used to treat a multitude of ailments. I …
Aetiology and Management of IOL Dislocations.
Khoramnia R, Baur ID, Auffarth GU. Khoramnia R, et al. Klin Monbl Augenheilkd. 2023 Aug;240(8):971-980. doi: 10.1055/a-2074-9028. Epub 2023 Jul 12. Klin Monbl Augenheilkd. 2023. PMID: 37494272 English, German.
The decision of which method to use should be made case by case and in accordance with the surgeon's preference....
The decision of which method to use should be made case by case and in accordance with the surgeon's preference....
A Comparative Analysis of the Effects of Misaligning Different Trifocal Intraocular Lenses.
Yan W, Auffarth GU, Khoramnia R, Łabuz G. Yan W, et al. J Clin Med. 2024 Dec 31;14(1):187. doi: 10.3390/jcm14010187. J Clin Med. 2024. PMID: 39797271 Free PMC article.
When decentration was induced at a 4.5 mm distance, its effect was more evident in conditions that were closer to each IOL's SA correction. A tilt of 5 had a lesser impact than 1 mm decentration, with the effect being more severe at 4.5 mm. ...
When decentration was induced at a 4.5 mm distance, its effect was more evident in conditions that were closer to each IOL's SA corre …
Review of Mix-and-Match Approach and Binocular Intraocular Lens Systems.
Naujokaitis T, Łabuz G, Khoramnia R, Auffarth GU. Naujokaitis T, et al. J Clin Med. 2025 Jun 16;14(12):4263. doi: 10.3390/jcm14124263. J Clin Med. 2025. PMID: 40566008 Free PMC article. Review.
In the mix-and-match approach, the surgeon selects the IOL models to be combined according to the clinical situation, the patient's needs, and personal preference. Combinations described in the literature include, among others, two bifocal IOLs, an extended-depth-of-focus …
In the mix-and-match approach, the surgeon selects the IOL models to be combined according to the clinical situation, the patient's n …
Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): Study protocol of a phase III trial.
Poli S, Grohmann C, Wenzel DA, Poli K, Tünnerhoff J, Nedelmann M, Fiehler J, Burghaus I, Lehmann M, Glauch M, Schadwinkel HM, Kalmbach P, Zeller J, Peters T, Eschenfelder C, Agostini H, Campbell BC, Fischer MD, Sykora M, Mac Grory B, Feltgen N, Kowarik M, Seiffge D, Strbian D, Albrecht M, Alzureiqi MS, Auffarth G, Bäzner H, Behnke S, Berberich A, Bode F, Bohmann FO, Cheng B, Czihal M, Danyel LA, Dimopoulos S, Pinhal Ferreira de Pinho JD, Fries FN, Gamulescu MA, Gekeler F, Gomez-Exposito A, Gumbinger C, Guthoff R, Hattenbach LO, Kellert L, Khoramnia R, Kohnen T, Kürten D, Lackner B, Laible M, Lee JI, Leithner C, Liegl R, Lochner P, Mackert M, Mbroh J, Müller S, Nagel S, Prasuhn M, Purrucker J, Reich A, Mundiyanapurath S, Royl G, Salchow DJ, Schäfer JH, Schlachetzki F, Schmack I, Thomalla G, Tieck Fernandez MP, Wakili P, Walter P, Wolf A, Wolf M, Bartz-Schmidt KU, Schultheiss M, Spitzer MS. Poli S, et al. Int J Stroke. 2024 Aug;19(7):823-829. doi: 10.1177/17474930241248516. Epub 2024 Jun 25. Int J Stroke. 2024. PMID: 38591748 Free article.
126 results